Références

Covid-19 - Références bibliographiques

Coronavirus humains (HCOV)

- Les coronavirus humains (HCoV)

A. Vabret et ali. Pathologie Biologie. Volume 57, n° 2 (mars 2009)

-  Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and Deltacoronavirus.

Patrick C. Y. Woo et al. American Society for Microbiology. Journal of Virology. 2012.

- Potential Factors Influencing Repeated SARS Outbreaks in China.

Zhong Sun et al. IJERPHn Volume 17, Issue 5. Published: 3 March 2020

Emergence du Sars-CoV-2

- A new coronavirus associated with human respiratory disease in China.

Fan Wu et al. Nature, volume 579. Published: 03 February 2020

- Introductions and early spread of SARS-CoV-2 in France.

Fabiana Gambaro et ali. Posted April 29, 2020. medRxiv preprint.

- Sars-CoV-2 (Covid-19) by the numbers.

Ynon M. Bar-On et al. Weizman Institute of Science. 30-03-2020

- The major genetic risk factor for severe COVID-19 is inherited from Neanderthals

Hugo Zeberg & Svante Pääbo. Nature. Published 30 September 2020

Origine animale des coronavirus

- Zoonotic origins of human coronaviruses.

Zi-Wei Ye et al. Int. J. Biol. Sci. 2020, Vol. 16

- A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Peng Zhou et al. Nature volume 579. Published: 03 February 2020

- Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins.

Tommy Tsan-Yuk Lam et alli. Nature. Published: 26 March 2020

- Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak.

Tao Zhang et al. Current Biology, Volume 30, Issue 7, 6 April 2020.

- A review of studies on animal reservoirs of the SARS coronavirus.

Zhengli Shi and Zhihong Hu. Virus Res. 2008. Published online 2007 Apr 23.

- Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins.

Xiao, Kangpeng et al. Nature. Published: 07 May 2020

- Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?

Ping Liu et al. PLOS, Published: May 14, 2020

- Retrouver les origines du SARS-CoV-2 dans les phylogénies de coronavirus.

Erwan Sallard et al. Med Sci (Paris). Volume 36, Numéro 8-9, Août–Septembre 2020

Mutations de Sars-CoV-2

- Genetic diversity and evolution of SARS-CoV-2.

Tung Phan. Infect Genet Evol. 2020 Jul. Published online 2020 Feb 21.

- Patient-derived mutations impact pathogenicity of SARS-CoV-2.

Hangping Yao et al. posted April 19, 2020. medRxiv preprint

- Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant.

Maria Pachetti et al. J Transl Med. 2020; 18. Published online 2020 Apr 22

- Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2.

B Korber et al. Posted May 05, 2020. biorxiv preprint

- Emergence of genomic diversity and recurrent mutations in SARS-CoV-2.

Lucy van Dorp et al. Infection, Genetics and Evolution, Available online 5 May 2020

Interactions avec des récepteurs cellulaires

- Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2.

Wenfei Song et al. PLOS. August 13, 2018

- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Daniel Wrapp et al. Science  13 Mar 2020

- Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.

Yushun Wan et al. J Virol. 2020 Mar 17

- Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection.

Junwen Luan et al. Biochemical and Biophysical Research Communications. Available online 19 March 2020.

- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Renhong Yan et al. Science. 2020 Mar 27.

- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Wanbo Tai et al. Cellular & Molecular Immunology (2020)

- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.

Shuai Xia et al. Cell Research, volume 30. Published: 30 March 2020

- Cell entry mechanisms of SARS-CoV-2.

Jian Shang et al. PNAS first published May 6, 2020.

- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Hoffmann et al. Cell. Mar 7, 2020; Graphical abstract.

- Structure of the RNA-dependent RNA polymerase from COVID-19 virus.

Yan Gao et al. Science  15 May 2020: Vol. 368, Issue 6492, pp. 779-782. Published online April 10, 2020

- Structure of replicating SARS-CoV-2 polymerase.

Hauke S. Hillen et al., Nature 2020. Published 21 May 2020

Variabilité génétique ACE2

- Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.

Yanan Cao et al. Cell Discovery volume 6. Published: 24 February 2020

- Individual Variation of the SARS-CoV2 Receptor ACE2 Gene Expression and Regulation.

Jiawei Chen et al. Preprints. Online: 12 March 2020

- ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian population.

Alessandra Renieri et ali. Posted April 06, 2020. MedRxiv.

- ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.

Rosanna Asselta et al. Posted April 11, 2020. MedRxiv.

Réponse immune

- COVID-19 infection: the perspectives on immune responses.

Shi, Y.et al. Cell Death Differ 27. Published: 23 March 2020

- Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia.

Pistes thérapeutiques

- Coronavirus Main Proteinase (3CL^pro) Structure: Basis for Design of Anti-SARS Drugs.

Kanchan Anand et al. Science  13 Jun 2003.

- Learning from the past: possible urgent prevention and treatement options for severe acute respiratory infections caused by 2019-nCov.

Jared R Morse et al. European chemical societies, ChemBioChem. 05 February 2020.

- Updated approaches against SARS-CoV-2.

Li H et al. Antimicrob Agents Chemother. 2020 Mar 23

- Structure of M^pro from COVID-19 virus and discovery of its inhibitors.

Zhenming Jin et al. medRxiv preprients. Posted March 29, 2020.

- Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence.

Beth Russell et al. Ecancermedicalscience. 2020

- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

Gordon, David E et al. Nature. May 1, 2020

- Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.

Wanchao Yin et al. Science  01 May 2020

- A human monoclonal antibody blocking SARS-CoV-2 infection.

Chunyan Wang et al. Nat Commun. 2020; 11. Published online 2020 May 4

- An Evidence Based Perspective on mRNA-SARSCoV-2 Vaccine Development.

Fuzhou Wang et al. Med Sci Monit. 2020; 26. Published online 2020 May 5

- COVID-19 vaccine development and a potential nanomaterial path forward.

Matthew D. Shin et ali. Nature nanotechnology. Published: 15 July 2020

- Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.

Zhe Lv et al. Science  23 July 2020

Synthèses

- SARS — beginning to understand a new virus.

Konrad Stadler et al. Nature Reviews Microbiology volume 1, pages209–218(2003)

- Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.

Yanwei Li et al. Pharmacol Res. 2020 Jul; Published online 2020 Apr 14.

- Phylodynamique du COVID-19 en France : variations temporelles de la croissance épidémique.

Groupe de modélisation de l’équipe ETE (Laboratoire MIVEGEC, CNRS, IRD, Université de Montpellier)

9 avril 2020 (mis à jour le 24 avril)

- COVID-19: The first documented coronavirus pandemic in history.

Yen-ChinLiu et al. Biomedical Jornal. Available online 5 May 2020

- The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review.

C. Li et al. Eur Rev Med Pharmacol Sci. May 7, 2020

- Coronavirus disease 2019: a clinical review.